LOCALLY ADVANCED

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery in 103 women with locally advanced cervical cancer. The goal is to see if this approach can shrink tumors enough to allow less extensive…

This study tests whether a digital app that tracks symptoms weekly can help doctors better manage side effects in people with advanced kidney cancer taking cabozantinib and nivolumab. About 83 patients will use the app to report how they feel, and doctors can adjust treatment bas…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The trial will enroll about 355 adults and is the first time this drug i…

This phase 2 pilot study is testing a new drug called CUE-101, alone or combined with pembrolizumab, in 30 people with newly diagnosed, locally advanced HPV-16 head and neck cancer. The goal is to see if the combination boosts the immune system's ability to fight the cancer befor…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…

This Phase 2 trial is testing whether combining two immunotherapy drugs (cemiplimab and fianlimab) with radiation can shrink tumors in people with locally advanced non-small cell lung cancer who haven't had treatment yet. The study will enroll 76 participants and measure how well…

This early study tests a new device called YntraDose™ that delivers a single dose of radiation directly into pancreatic tumors that cannot be removed by surgery. Ten participants will receive the implant along with standard chemotherapy. The main goals are to see if the procedure…

This clinical trial is testing whether adding a device that delivers low-intensity electric fields (Tumor Treating Fields) to targeted radiation therapy can slow tumor growth in people with locally advanced pancreas cancer. Participants will receive radiation for five days and us…

This study tests a new way to give radiation therapy for stage III lung cancer that cannot be removed by surgery. It combines a smaller, faster radiation field with standard chemotherapy and an immunotherapy drug called durvalumab. The goal is to see if this approach helps more p…

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study is testing whether a less invasive procedure called target axillary dissection (TAD) can accurately check for cancer spread in the lymph nodes of people with locally advanced breast cancer after chemotherapy. The goal is to see if TAD can replace more extensive lymph n…